RE:RE:RE:RE:RE:RE:RE:NASH in the ATM Prospectus
It seems there are so many different ways cancer can eventually take you it must be difficult to pick out a drug signal from all that noise. I expect you rely on the clinical experience of doctors and the trial safety monitors to assess whether death (or serious events) fits with the usual course of terminal cancer or with that patients past clinical history. If the patient died of liver failure, did they have liver tumours, did they have rising liver enzymes prior to the trial, are other patients showing rising liver enzymes when they start the drug. I guess the death should lead whoever is monitoring this to start to look for patterns. If they can't see patterns or they can chalk the death down to normal disease progress then you continue on until a pattern emerges with subsequent patients.
palinc2000 wrote: The risks section in any prospectus is always a bit frightening but they are potential risks and the risk section in biotechs are even more frightening..
There is also a smaller section for the Risks in Phase 1 and there is one that is quite interesting which is when a patient dies and many patients are likely to die because they are very sick to start with how do they determine if the death is due to natural causes or if it is an averse side effect of taking TH 1902... Qwerty?